Home > Journals > International Angiology > Past Issues > International Angiology 2018 August;37(4) > International Angiology 2018 August;37(4):269-76

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW   Freefree

International Angiology 2018 August;37(4):269-76

DOI: 10.23736/S0392-9590.18.03982-2

Copyright © 2018 EDIZIONI MINERVA MEDICA

language: English

Risk assessment as a guide for the prevention of cancer-associated thromboembolism

Ahmed AL-OGAILI 1 , Harry E. FUENTES 1, Alfonso J. TAFUR 2, Joseph CAPRINI 3

1 Department of Internal Medicine, John H. Stroger Jr, Hospital of Cook County, Chicago, IL, USA; 2 Department of Medicine, Cardiology-Vascular Medicine, Northshore University HealthSystem, Evanston, IL, USA; 3 Pritzker School of Medicine, NorthShore University HealthSystem, Evanston, IL, USA


PDF


Venous thromboembolism (VTE) is a major source of morbidity and mortality among patients diagnosed with cancer. In addition to an increased risk of VTE, patients with cancer are at higher risk of bleeding while receiving therapeutic anticoagulation. Aggressive and targeted thromboprophylaxis is a crucial practice to avoid the dreaded complications of VTE. Risk assessment models (RAM) are tools developed to identify high-risk patients in whom thromboprophylaxis is beneficial. This review describes the most validated VTE RAMs in patients with cancer.


KEY WORDS: Thrombosis - Venous thromboembolism - Neoplasms - Primary prevention

top of page